Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
45.57
+1.30 (2.94%)
At close: May 12, 2025, 4:00 PM
45.57
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $111.59M in the quarter ending March 31, 2025, with 61.20% growth. This brings the company's revenue in the last twelve months to $379.25M, up 69.31% year-over-year. In the year 2024, Mirum Pharmaceuticals had annual revenue of $336.89M with 80.76% growth.
Revenue (ttm)
$379.25M
Revenue Growth
+69.31%
P/S Ratio
5.77
Revenue / Employee
$1,177,798
Employees
322
Market Cap
2.26B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MIRM News
- 3 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 days ago - Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL - Business Wire
- 5 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 8 days ago - Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities - Seeking Alpha
- 12 days ago - Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Business Wire
- 14 days ago - Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses - Business Wire
- 4 weeks ago - Mirum's LIVMARLI Now FDA Approved in Tablet Formulation - Business Wire